Healthcare
Janux Therapeutics, Inc.(JANX)
Live Price
Offline$14.22
+0.49% today
1Y Change
-38.81%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $870.00M
- Revenue Growth
- -5.6%
- EPS Growth
- -43.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Janux Therapeutics, Inc. (JANX) is a Healthcare stock with a market cap of $870.00M and listed on NASDAQ. The stock last traded around $14.22 and down 38.8% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -5.6%, EPS growth of -43.0%, a dividend yield of 0.0%. What stands out right now is revenue -5.6%, EPS -43.0%, free cash flow -88.5% with operating margin -881.8% and ROIC -16.0%. Valuation already assumes a fairly strong business story at price/sales 48.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines JANX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-5.6% vs +7.6% peer median
Operating Margin
Below sector median
-881.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -5.6% and EPS is at -43.0%, with operating margin around -881.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.5% | +0.1% | -5.8% |
2026 Feb 26, 2026 | +21.5% | -1.4% | +1.2% | -1.2% |
2025 Nov 6, 2025 | +35.0% | -7.6% | -4.2% | -42.4% |
Benchmark Edge
JANX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JANX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JANX Max Drawdown
-64.94%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JANX and SPY.
Company Overview
Janux Therapeutics, Inc.
NASDAQ Global Market
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
- Leadership
- David Alan Campbell
- IPO Date
- Jun 11, 2021
- Employees
- 91
- Street Address
- 11099 North Torrey Pines Road
- Mailing
- San Diego, CA, 92037
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 750 4700
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 48.7
- Price/Book
- 0.9
Growth
- Revenue
- -5.6%
- EPS
- -43.0%
- Free Cash Flow
- -88.5%
Profitability
- Gross Margin
- 47.2%
- Operating Margin
- -881.8%
- Net Margin
- -635.5%
- ROE
- -11.5%
- ROIC
- -16.0%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 39.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.